@Article{096504016X14685034103590,
AUTHOR = {Tao Xie, Yao Li, Shi-Lei Li, Hai-Feng Luo},
TITLE = {Astragaloside IV Enhances Cisplatin Chemosensitivity  in Human Colorectal Cancer via Regulating NOTCH3},
JOURNAL = {Oncology Research},
VOLUME = {24},
YEAR = {2016},
NUMBER = {6},
PAGES = {447--453},
URL = {http://www.techscience.com/or/v24n6/57002},
ISSN = {1555-3906},
ABSTRACT = {Although astragaloside IV exhibits anti-inflammation, immunoregulatory, and anticancer properties, the 
chemosensitization effects of astragaloside IV in colorectal cancer have never been reported. Our study 
tested whether astragaloside could increase cisplatin sensitivity in colorectal cancer. CCK-8 assay was used 
to measure the cell viability of colorectal cancer cells. Quantitative real-time PCR and Western blot were 
performed to determine the mRNA and protein expression, respectively. Our data revealed that astragaloside 
IV administration significantly suppressed the cell growth of colorectal cancer cells, whereas no obvious 
cytotoxicity of astragaloside IV was observed in nonmalignant colonic cells. In addition, combined treatment with astragaloside IV dramatically elevated the chemosensitivity of colorectal cancer cells to cisplatin. 
Mechanical investigation revealed that the mRNA and protein expression of NOTCH3 was significantly 
lower in cisplatin and astragaloside IV-treated cells compared with cells treated with cisplatin alone. On 
the contrary, no obvious changes in tumor cell growth were shown after upregulation of NOTCH3 whether 
in the presence or absence of astragaloside IV. Thus, our data demonstrate that astragaloside IV increases 
the chemosensitivity of colorectal cancer cells to cisplatin, at least partly, through inhibition of NOTCH3. 
This study suggests that combined therapy with astragaloside IV might be a novel therapeutic approach for 
colorectal cancer.},
DOI = {10.3727/096504016X14685034103590}
}